RxDoctor Payments Data

Scott Anzalone, MD

Family Medicine · Logan, OHNPI 1275544579

Payments from drug & device makers

$852in general payments, 2019–2025

Across 51 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$243
  • Novo Nordisk$74
  • Lilly USA, LLC$72
  • Johnson & Johnson$68
  • AbbVie$40
  • Paratek Pharmaceuticals, Inc.$34
  • plus $322 from 19 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$852 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$99,659
Medicare patients
223
Services billed
2,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tresiba Flextouch U-200Insulin Degludec49$75,880
JardianceEmpagliflozin54$71,021
EliquisApixaban57$60,102
OzempicSemaglutide37$55,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$38,051
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$35,482
Repatha SyringeEvolocumab32$33,070
MounjaroTirzepatide22$30,609
RybelsusSemaglutide17$24,039
XareltoRivaroxaban13$21,071
JanuviaSitagliptin Phosphate12$20,060
VraylarCariprazine Hcl12$17,029
MyrbetriqMirabegron13$14,725
Breo ElliptaFluticasone/Vilanterol11$6,091
Atorvastatin Calcium322$2,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$74$79,50254 claims
Lilly USA, LLCMounjaro$72$30,60922 claims
Johnson & JohnsonXarelto$68$21,07113 claims
MerckJanuvia$30$20,06012 claims
AbbVieVraylar, Synthroid$40$17,94150 claims
Astellas Pharma US IncMyrbetriq$28$14,72513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Logan

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →